Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / November 15, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX). Investors who purchased Ventyx securities are encouraged to obtain additional in...
2023-11-10 15:00:22 ET More on the markets Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble SPY: Double-Barreled Buy Signal Works Again, Now What? SPY: Don't Believe Mr. Market And Stay On The Sidelines Invest...
SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announ...
2023-11-09 17:37:08 ET More on Ventyx Biosciences Ventyx Biosciences Now Has 2 Strikes Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation Oppenheimer downgrades Ventyx to perform, removes price target For further details see: Ventyx Bio...
Ventyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx...
The law firm of Kirby McInerney LLP is investigating potential claims against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX ). The investigation concerns whether Ventyx and/or certain of its officers have violated the federal securities law...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
2023-11-07 22:52:52 ET More on Ventyx Biosciences Ventyx Biosciences Now Has 2 Strikes Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript Biggest stock movers today: BioMarin,...
2023-11-07 17:28:33 ET Gainers: TransMedics ( TMDX ) +36% . Carbon Revolution Public Limited ( CREV ) +26% . EverQuote ( EVER ) +16% . TaskUs ( TASK ) +13% . TripAdvisor ( TRIP ) +12% . Losers: Ventyx Bioscien...
2023-11-07 12:51:35 ET Gainers: PaxMedica ( PXMD ) +78% . Jaguar Global Growth Corp I ( JGGC ) +62% . Transmedics Group ( TMDX ) +54% . Baiyu Holdings ( BYU ) +48% . Fathom Digital Manufacturing Corporation ( FATH ) +46% . Ko...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...